Literature DB >> 2236476

Factors determining success and energy requirements for cardioversion of atrial fibrillation.

G W Dalzell1, J Anderson, A A Adgey.   

Abstract

Factors thought to affect the success of and energy requirements for cardioversion of atrial fibrillation were studied in 80 (49 male, 31 female) patients aged 21-88 (mean 61.5 years). Transthoracic impedance was measured in advance of the countershock using a 30 kHz low amplitude AC current passed through self-adhesive ECG/defibrillator pads (diameters 8-12 cm) applied to the chest in the antero-posterior (AP) position in 57 patients and the anteroapical (AA) position in 23 patients. Mean transthoracic impedance for all patients was 69.3 +/- 16 (SD) ohms (range 39-131 ohms), but transthoracic impedance was significantly greater in the AA than the AP position (75.4 +/- 13 vs. 66.7 +/- 16 ohms, p = 0.02). Initial energy was 50 J (delivered) and was gradually increased to a maximum of 360 J if required. Cardioversion was successful in 73 of 80 (91.2 per cent), and low energy shocks (less than or equal to 200 J) were successful in 45 of 80 (56.2 per cent) patients. Using single factor analysis, sex, left atrial enlargement, electrode pad positions, aetiology of atrial fibrillation, presence of left ventricular failure, and prior treatment with verapamil or beta-adrenergic blockers were not significant determinants of cardioversion success or success of low energy shocks but prior treatment with digoxin was, both for cardioversion success and success at low energies. In patients with transthoracic impedance less than or equal to 70 ohms, low energy shocks were more often successful (33 or 50, 66 per cent) than in patients with transthoracic impedance greater than 70 ohms (12 of 30, 40 per cent), p = 0.04. Using univariate analysis, cardioversion success with low energy shocks was not only significantly associated with prior treatment with digoxin but also with the duration of atrial fibrillation (24 hours to one month and one month to three years) and for shocks of less than or equal to 100 J, with prior treatment with amiodarone. Multifactorial linear regression analysis selected, in rank order, only duration of atrial fibrillation of 24 hours to less than one month and one month to three years as significant predictors of both cardioversion success irrespective of shock strength, and success of low energy shocks.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2236476

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  11 in total

Review 1.  Report of the NASPE/NHLBI Round Table on Future Research Directions in Atrial Fibrillation. North American Society of Pacing and Electrophysiology.

Authors:  S Saskena; M J Domanski; E J Benjamin; A J Camm; M D Ezekowitz; B J Gersh; J Jalife; G V Naccarelli; R E Vlietstra; D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2001-09       Impact factor: 1.900

2.  Direct Current Cardioversion of Atrial Arrhythmias in Adults With Cardiac Amyloidosis.

Authors:  Edward A El-Am; Angela Dispenzieri; Rowlens M Melduni; Naser M Ammash; Roger D White; David O Hodge; Peter A Noseworthy; Grace Lin; Sorin V Pislaru; Alexander C Egbe; Martha Grogan; Vuyisile T Nkomo
Journal:  J Am Coll Cardiol       Date:  2019-02-12       Impact factor: 24.094

Review 3.  Atrial fibrillation: choosing an antiarrhythmic drug.

Authors:  Todd Rudo; Peter Kowey
Journal:  Curr Cardiol Rep       Date:  2006-09       Impact factor: 2.931

4.  Improvement of the myocardial performance index in atrial fibrilation patients treated with amiodarone after cardioversion.

Authors:  Feyzullah Besli; Cengiz Basar; Mesut Kecebas; Yasin Turker
Journal:  J Interv Card Electrophysiol       Date:  2015-01-16       Impact factor: 1.900

5.  Higher energy monophasic DC cardioversion for persistent atrial fibrillation: is it time to start at 360 joules?

Authors:  C Boos; M D Thomas; A Jones; E Clarke; G Wilbourne; R S More
Journal:  Ann Noninvasive Electrocardiol       Date:  2003-04       Impact factor: 1.468

Review 6.  The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations.

Authors:  S Nattel; T Hadjis; M Talajic
Journal:  Drugs       Date:  1994-09       Impact factor: 9.546

7.  The role of biphasic shocks for transthoracic cardioversion of atrial fibrillation.

Authors:  Simon J Walsh; Ben M Glover; A A Jennifer Adgey
Journal:  Indian Pacing Electrophysiol J       Date:  2005-10-01

8.  Rate-control or rhythm-control: where do we stand?

Authors:  L Testa; G Trotta; A Dello Russo; M Casella; G Pelargonio; F Andreotti; F Bellocci
Journal:  Indian Pacing Electrophysiol J       Date:  2005-10-01

9.  Current status of internal cardioversion in atrial fibrillation.

Authors:  Andreas Plewan; Eckhard Alt
Journal:  Indian Pacing Electrophysiol J       Date:  2002-04-01

10.  A review of direct current cardioversions for atrial arrhythmia.

Authors:  S D Johnston; T G Trouton; C Wilson
Journal:  Ulster Med J       Date:  1998-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.